Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Blood (2025) 146 (Supplement 1): 2168.

https://doi.org/10.1182/blood-2025-2168

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Blood (2025) 146 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2025-3930

Published: 2025

Journal Articles

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

Yoshinobu Konishi, Giuseppe Tarantino, Yiwen He, Romanos Sklavenitis-Pistofidis, Sujal Shah, Ruben Carrasco, Scott Rodig, Jon Aster, Gad Getz, David Liu, Irene Ghobrial

Blood (2025) 146 (Supplement 1): 5702.

https://doi.org/10.1182/blood-2025-5702

Published: 2025

Journal Articles

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Blood (2025) 146 (1): 89–103.

https://doi.org/10.1182/blood.2024025102

Published: 2025

Includes: Supplemental data

Journal Articles

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Blood (2024) 144 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2024-203937

Published: 2024

Journal Articles

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2024-203684

Published: 2024

Journal Articles

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Blood (2024) 144 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2024-203517

Published: 2024

Journal Articles

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Blood (2024) 144 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2024-205705

Published: 2024

Journal Articles

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Blood (2024) 144 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2024-209286

Published: 2024

Journal Articles

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Blood (2024) 144 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2024-194368

Published: 2024

Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz

Blood (2024) 144 (Supplement 1): 492.

https://doi.org/10.1182/blood-2024-204132

Published: 2024

Journal Articles

Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy

Hao Sun, Romanos Sklavenitis-Pistofidis, Xia Liu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Andres Felipe Ramirez Gamero, Catherine A. Flynn, Christopher J Patterson, Mu Hao, Lu-Gui Qiu, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Shirong Liu, Steven P. Treon

Blood (2024) 144 (Supplement 1): 4338.

https://doi.org/10.1182/blood-2024-211597

Published: 2024

Journal Articles

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2024-206540

Published: 2024

Journal Articles

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Nayda Bidikian, Francesco Corrado, Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Michelle P. Aranha, Ting Wu, Michael Timonian, Shonali Midha, Elizabeth K. O'Donnell, Yuxin Liu, Sophie Magidson, Ashlee Strutevant, Kenneth C. Anderson, Nikhil C. Munshi, Omar Nadeem, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 488.

https://doi.org/10.1182/blood-2024-207299

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only